Jinhao medical issue price of 16.8 yuan, equivalent to 74.47% of the average closing price of the last 20 trading days with transactions in the six months prior to the application for public offering of 22.56 yuan / share. The issue price of RMB 16.8 corresponds to a diluted P/E ratio of 20.37 times the 2020 net profit after extraordinary gains and losses if the over-allotment option is not exercised. The company's industry is "manufacturing" in the "special equipment manufacturing (C35)". As of September 24th, the average static price-earnings ratio of the special equipment manufacturing industry in the last month published by CSI is 41.97 times. The Company's products include hearing aids, nebulizers, and anti-decubitus air mattresses. Competitors of hearing aid products include Rishengda Hearing Group Corporation, Sonova Hearing Group Corporation of Switzerland, EARGO Corporation of the United States, Oshida Hearing Technology (Xiamen) Co.
The listed companies and New Third Board listed companies that are comparable to the business of Jinhao Medical are Yuyue Medical, Jiu'an Medical, Lexin Medical, Lude Medical, and Fujian Taier. Most of the products of Jinhao Medical and the comparable companies are sold for domestic and foreign markets, of which Jiu'an Medical, Lude Medical and the company have adopted the ODM sales model, and also established its own brand.
Jinhao medical 16.8 yuan issue, valuation of 20 times, listed on the NSE is also a listed company, the valuation is estimated at more than 30 times, so the expected increase in 50-100%.